{"nctId":"NCT00340834","briefTitle":"Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase","startDateStruct":{"date":"2006-05"},"conditions":["Multiple Sclerosis"],"count":1292,"armGroups":[{"label":"Fingolimod 1.25 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Fingolimod 1.25 mg"]},{"label":"Fingolimod 0.5 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Fingolimod 0.5 mg"]},{"label":"Interferon β-1a 30 µg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Interferon β-1a 30 µg"]}],"interventions":[{"name":"Fingolimod 1.25 mg","otherNames":["FTY720"]},{"name":"Fingolimod 0.5 mg","otherNames":["FTY720"]},{"name":"Interferon β-1a 30 µg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female patients between ages 18-55 with a diagnosis of multiple sclerosis (MS)\n* Patients with a relapsing-remitting disease course\n* Patients with Expanded Disability Status Scale (EDSS) score of 0-5.5\n\nExclusion Criteria:\n\n* Patients with other chronic disease of the immune system, malignancies, acute pulmonary disease, cardiac failure, etc\n* Pregnant or nursing women\n* Patients who cannot tolerate treatment with an interferon\n\nOther protocol-defined inclusion/exclusion criteria applied to the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"55 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Estimated Annualized Aggregate Relapse Rate (ARR) in the Core Phase of the Study","description":"The ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was calculated using negative binomial regression adjusted by treatment, country, number of relapses in the previous 2 years, and the baseline Expanded Disability Status Scale score.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.203","spread":null},{"groupId":"OG001","value":"0.161","spread":null},{"groupId":"OG002","value":"0.331","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of New or Newly Enlarged T2 Lesions in Comparison With Baseline in the Core Phase of the Study","description":"The number of new or newly enlarged T2 lesions in comparison to baseline was assessed with T2-weighted magnetic resonance image (MRI) scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2-weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"3.23"},{"groupId":"OG001","value":"1.6","spread":"3.16"},{"groupId":"OG002","value":"2.6","spread":"5.50"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Free of 3-month Disability Progression Assessed With the Expanded Disability Status Scale (EDSS) at the End of the Core Phase of the Study","description":"The EDSS is a scale for assessing disability in 8 functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel \\& bladder, cerebral, other functions). An overall score ranging from 0 (normal) to 10 (death due to MS) is calculated. Disability progression was determined by the EDSS score based on the following criteria: One point increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point increase in patients with baseline EDSS score of 5.5 or above. Percent of patients free of disability progression was calculated using the Kaplan-Meier method.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.3","spread":null},{"groupId":"OG001","value":"94.1","spread":null},{"groupId":"OG002","value":"92.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Estimated Annualized Aggregate Relapse Rate (ARR) in the Core and Extension Phases of the Study","description":"The ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was calculated using negative binomial regression adjusted by treatment, country, number of relapses in the previous 2 years, and the baseline Expanded Disability Status Scale score.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.156","spread":null},{"groupId":"OG001","value":"0.182","spread":null},{"groupId":"OG002","value":"0.266","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.116","spread":null},{"groupId":"OG001","value":"0.110","spread":null},{"groupId":"OG002","value":"0.121","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.192","spread":null},{"groupId":"OG001","value":"0.166","spread":null},{"groupId":"OG002","value":"0.271","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of New or Newly Enlarged T2 Lesions in the Extension Phase of the Study","description":"The number of new or newly enlarged T2 lesions in comparison to baseline was assessed with T2-weighted magnetic resonance image (MRI) scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2-weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.08","spread":"2.644"},{"groupId":"OG001","value":"0.87","spread":"1.624"},{"groupId":"OG002","value":"0.97","spread":"1.923"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.40","spread":"3.418"},{"groupId":"OG001","value":"1.04","spread":"4.408"},{"groupId":"OG002","value":"0.72","spread":"1.733"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.97","spread":"1.682"},{"groupId":"OG001","value":"0.59","spread":"1.438"},{"groupId":"OG002","value":"0.49","spread":"1.483"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.75","spread":"7.248"},{"groupId":"OG001","value":"0.86","spread":"2.674"},{"groupId":"OG002","value":"1.03","spread":"4.350"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Free of 3-month and 6-month Disability Progression Assessed With the Expanded Disability Status Scale (EDSS) at the End of the Extension Phase of the Study","description":"The EDSS is a scale for assessing disability in 8 functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel \\& bladder, cerebral, other functions). An overall score ranging from 0 (normal) to 10 (death due to MS) is calculated. Disability progression was determined by the EDSS score based on the following criteria: One point increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point increase in patients with baseline EDSS score of 5.5 or above. Percent of patients free of disability progression was calculated using the Kaplan-Meier method.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.01","spread":null},{"groupId":"OG001","value":"71.28","spread":null},{"groupId":"OG002","value":"73.40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.54","spread":null},{"groupId":"OG001","value":"79.76","spread":null},{"groupId":"OG002","value":"81.61","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":45,"n":420},"commonTop":["Nasopharyngitis","Headache","Influenza like illness","Fatigue","Upper respiratory tract infection"]}}}